Vasile Musteata

PROGNOSIS FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH PRIMARY INVOLVEMENT OF THE SPLEEN

Larisa Musteaţă, Ion Corcimaru, Vasile Musteata

The increased morbidity and DALY rates in the working-age population, commonly late diagnosis and unfavorable socio-economic impact of non-Hodgkin lymphomas (NHL) can be considered as key issues of hemato-oncology. Clinico-hematological patterns of primary NHL of the spleen indicate the need of searching …

Epidemiological spectrum and diagnosis patterns of hematological malignancies in the republic of moldova

Vasile Musteata, Larisa Catrinici, V. Stratan, Larisa Musteaţă

hematol transfus cell ther. 2 0 2 0;4 2(S 1):S35-S78 S39 (moderate risk) and Binet B (moderate risk).However, in consideration of his weight loss and symptomatic extranodal involvement, a chemotherapy protocol with bendamustine and the CD20 antibody rituximab (BR) was initiated.BR treatment …

ro (code pays fourni par la source)

Stevens–Johnson syndrome secondary to rituximab administration in a chronic lymphocytic leukemia patient

Victor Tomacinschii, M. Robu, Sanda Buruiana, Vasile Musteata

md (code pays fourni par la source)

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata et autres

Primary immune thrombocytopenia (ITP) is a predominantly immunoglobulin G (IgG)-autoantibody-mediated disease characterized by isolated thrombocytopenia. Rozanolixizumab, a subcutaneously infused humanized monoclonal anti-neonatal Fc receptor (FcRn) antibody, reduced serum IgG in healthy volunteers. In this phase 2, multicenter, open-label study, patients with persistent/chronic …

pl, es, gb, de, us (code pays fourni par la source)

A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Adolfo Enrique Diaz Duque, Tetiana Perekhrestenko, Vasile Musteata, Mamia Zodelava et autres

TPS8074 Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable of forcing internalization, self-routing through intracellular compartments …

us, ca (code pays fourni par la source)

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, Vasile Musteata, Mamia Zodelava, Steven I. Park et autres

Background: The near ubiquity and persistence of CD20 expression in B-cell malignancies provides a strong rationale for novel CD20-directed therapies. MT-3724 is a novel engineered toxin body comprised of an anti-CD20 single chain variable fragment genetically fused to Shiga-like toxin A subunit, …

us (code pays fourni par la source)

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata et autres

Introduction Rozanolixizumab targets the human neonatal Fc receptor (FcRn). By blocking IgG recycling, this first-in-class subcutaneously (SC) infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. We report the completed Phase II, …

pl, es, gb, de, us (code pays fourni par la source)

S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY

Tadeusz Robak, Miroslaw Kazmierczak, Isidro Jarque, Vasile Musteata et autres

Background: Rozanolixizumab, a subcutaneous (SC) monoclonal antibody specific for the human neonatal Fc receptor (FcRn), is being developed with the aim of improving the lives of people with immunoglobulin G (IgG)‐mediated autoimmune diseases, by reducing pathogenic IgG autoantibodies. Aims: To report a …

pl, cn, es, gb, de, us (code pays fourni par la source)

Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis

Tadeusz Robak, Isidro Jarque, Vasile Musteata, Peter C. Kiessling et autres

Abstract Introduction Rozanolixizumab is a humanized, high-affinity, anti-human neonatal Fc receptor (FcRn) monoclonal antibody, developed with the aim of reducing levels of pathogenic immunoglobulin G (IgG) in autoimmune and alloimmune diseases. In a first-in-human (FIH) healthy subject trial (NCT02220153), single-dose rozanolixizumab was …

pl, de, gb, us, be (code pays fourni par la source)

Good clinical practice in chronic myeloid leukemia: advances and prospects at the Institute of Oncology of Moldova.

Vasile Musteata